Myopia care, reimagined

Clear sight shouldn't be a privilege.

VitaBildung is building a new standard for myopia management — helping clinicians catch progression earlier, and helping patients access the right treatment sooner, regardless of where they're seen.

Founded by a medical student Focus myopia progression & access
VitaBildung logo — an eye and a medical cross inside two converging V shapes, representing Vision, Innovation, and Care
~30%
of the world's population is projected to be myopic within the coming decades
Years
of unmanaged progression before many patients ever see a specialist
1 protocol
designed to work across ophthalmology, optometry, and primary care
The problem

Myopia care is fragmented — and often arrives too late

Most tools either assume a fully-equipped ophthalmology practice, or offer no real clinical structure at all. The gap in between is where patients fall through.

Detected late

Progression is often flagged only once a child's prescription has already worsened significantly — after the easiest window for intervention has passed.

Inconsistent across providers

What a patient is told often depends entirely on which type of provider they happen to see first — there's no shared, standardized pathway.

Out of reach

Surgical correction and specialist care remain financially or geographically inaccessible for a large share of the patients who need help most.

Curious where you stand?

Take our 60-second risk check to see whether your child's myopia pattern is worth a closer look.

Try the risk check
Our approach

One protocol, from first visit to long-term follow-up

VitaBildung is developing a structured myopia management pathway — designed to give every provider, at every level of care, a clear next step.

①

Assess

A structured intake gathers the patient information that actually predicts risk — not just a snapshot of their current prescription.

②

Guide treatment

Risk level maps to a clear set of options — from lifestyle changes through to escalation and specialist referral — suited to what's actually appropriate for that patient.

③

Follow through

Review timing and outcome tracking are built into the protocol, so progress — or lack of it — never goes unnoticed for long.

How we're different

Most tools solve one piece. We built one record.

A side-by-side look at how myopia-management tools typically work today, and where VitaBildung's approach diverges.

Dimension
Typical existing tools
VitaBildung
How a measurement was taken
Treated as interchangeable, regardless of the instrument or method used to capture it
Recorded as structured metadata and corrected for before any score is calculated
Dilation status
Standard for diagnosis, but rarely factored into the risk-scoring logic itself
An explicit input that adjusts the underlying measurements before they're scored
What "normal" means for this patient
Age used loosely; sex and ethnicity rarely built into the baseline at all
A baseline adjusted for age, sex, and ethnicity together, not age alone
Bad or inconsistent data
Usually still produces a confident-looking score regardless of input quality
A built-in plausibility check can halt the process and ask for a re-measurement first
Progression risk vs. surgical candidacy
Handled by separate, unconnected tools — a myopia app and a LASIK screener don't talk to each other
Both evaluated from the same patient record, as two independent questions answered together
Two eyes progressing differently
A single combined score per patient, or two reports the clinician has to reconcile by hand
Each eye is scored independently, with an explicit check for whether one plan fits both or two are needed
This is our own good-faith comparison to publicly described approaches, not a claim about any specific competitor or product by name.
Where we are

The road from prototype to platform

Early, deliberate, and honest about it — here's the actual sequence, not a polished version of it.

2025 – 2026
Complete

Core protocol designed

The underlying assessment and treatment-matching logic is built and internally tested against worked clinical scenarios, including a bilateral (two-eye) scoring extension.

Q3 2026
In progress

Patent protection

A complete invention disclosure is finished and is moving toward attorney engagement: formal prior-art search, then a provisional filing to establish priority.

Q4 2026 – Q1 2027
Ahead

Clinical validation

Every coefficient in the current prototype is a placeholder until it's been checked against real outcomes data. This stage replaces assumptions with evidence before anything reaches a patient.

2027
Planned

Production-grade platform

Hardening the prototype into a deployable application for clinics, with persistent records, role-based access, and a downloadable desktop build.

2027 and beyond
Future

Wider access & commercial rollout

Paid access for clinics once the platform and the science behind it are both ready — sequenced deliberately, in that order, not the reverse.

What we stand for

Vision. Innovation. Care.

Three words, one standard we hold every part of VitaBildung to.

Vision

Seeing the gap others miss

Myopia management has been built around the patients who can already afford full specialist care. We're building for everyone else too.

Innovation

Tools that earn their place

Every part of the protocol is grounded in published clinical evidence — not assumptions, and not guesswork dressed up as software.

Care

Built around the patient

The goal isn't a clever algorithm for its own sake. It's a child who needs a weaker prescription next year than they would have otherwise.

Have a stake in better myopia care?

Whether you're a clinician, researcher, or potential collaborator — we'd like to hear from you.

Get in touch